Relmada Therapeutics(RLMD)

Focus: Relmada is a public biotech focused on small molecules for pain, neurology, and oncology with a lean 5,000+ employee base headquartered in Florida. The company operates as a clinical-stage player with no approved products generating revenue.

Oncology Neurology

Profile data last refreshed 20h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Employees

5000+

Open Jobs

About Relmada Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Relmada Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Late-stage

5 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

REL-1017

Major Depressive Disorder

N/A

Clinical Trials (1)

NCT06009003Individual Patient Esmethadone (REL-1017) Expanded Access Program

N/A

Help build intelligence for Relmada Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline momentum in Phase 3 oncology (NDV-01 for bladder cancer, 3 trials) and neurology (REL-1017 for MDD, multiple Phase 3 programs) suggests near-term value inflection
Public company status enables equity upside participation and established corporate infrastructure vs. early-stage startups
Focus on high-need therapeutic areas (pain, depression, cancer) with clear unmet medical need and commercial potential

Watch Out For

Pre-revenue stage with $4M cash position and $79-98M annual net losses raises existential funding risk despite R&D spending of $46-55M annually
Zero active job openings at time of data collection indicates hiring freeze or potential restructuring constraints
No approved products means career growth depends entirely on pipeline success; clinical failure creates immediate employment volatility

Generated by Claude from Relmada Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

REL-1017

Neuropathic Pain

PHASE_1

Clinical Trials (1)

NCT03637361Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of REL-1017 (d-Methadone)

Phase 1

REL-1017

Neuropathic Pain

PHASE_1

Clinical Trials (1)

NCT03638869Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REL-1017 (d-Methadone)

Phase 1

REL-1017

Depressive Disorder, Major

PHASE_2

Clinical Trials (1)

NCT03051256Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD

Phase 2

NDV01 intravesical controlled release formulation of gemcitabine and docetaxel

Non Muscle Invasive Bladder Cancer

PHASE_2

Clinical Trials (1)

NCT06663137Open Label Study to Evaluate the Safety and Efficacy of NDV01 KIT in High Grade NMIBC

Phase 2

REL-1017

Major Depressive Disorder

PHASE_3

Clinical Trials (1)

NCT04688164A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)

Phase 3

NDV-01

Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)

PHASE_3

Clinical Trials (1)

NCT07313891A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT

Phase 3

REL-1017

Major Depressive Disorder

PHASE_3

Clinical Trials (1)

NCT04855760Safety of REL-1017 for Major Depressive Disorder

Phase 3

NDV-01

Bladder (Urothelial, Transitional Cell) Cancer

PHASE_3

Clinical Trials (2)

NCT07464145A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer

Phase 3

NCT07342517A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy

Phase 3

REL-1017

Major Depressive Disorder

PHASE_3

Clinical Trials (1)

NCT05081167A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2007

Portfolio: 11 clinical trials

Top TAs: Oncology, Neurology

SEC Filings: 2 available

Therapeutic Area Focus

Oncology

4 pipeline

Neurology

3 pipeline

Marketed

Pipeline

Financials (FY2025)

R&D Spend

$46M16%

Net Income

-$80M

Cash

$4M

Source: SEC 10-K Filing

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo